Cisplatin, carboplatin, and cyclophosphamide combination chemotherapy in advanced-stage ovarian carcinoma

An Eastern Cooperative Oncology Group pilot study

Jean L Grem, P. O'Dwyer, P. Elson, N. Simon, D. Trump, M. Frontiera, G. Falkson, S. Vogl

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Cyclophosphamide (CTX) 600 mg/m2, carboplatin 280 mg/m2, and cisplatin 50 mg/m2 were administered on day 1 every 4 weeks to 41 previously untreated ovarian cancer patients with residual disease greater than 2.0 cm after primary laparotomy. Of 22 patients with measurable disease treated with up to eight cycles of therapy, the overall clinical response rate was 73% (exact 95% confidence interval [CI], 50% to 89%), with 50% complete response (CR). Six of 11 clinical CR (cCR) patients underwent surgical restaging; three pathologic CRs (pCRs) and three pathologic partial responses (pPRs) with residual disease less than 2.0 cm were documented. Fourteen patients had nonmeasurable but assessable disease; the clinical response rate was 57% (CI, 29% to 82%) with two (14%) CRs. Second-look surgery was performed in one of the two cCR patients; a pPR was documented. Five patients with nonassessable disease were stable during chemotherapy; two underwent surgery and had pCRs. The median time to treatment failure (TTF) was 14.8 months, and median survival for the 41 patients is 26.7 months. Overall, 37% of the patients had progression-free intervals of at least 2 years, and 27% have survival times in excess of 3 years. Hematologic toxicity was substantial but manageable, with 58% and 66% experiencing a granulocyte nadir less than 500/μL and a platelet nadir less than 50,000/μL, respectively. One treatment-associated fatality occurred as a result of leukopenic sepsis and renal failure in the setting of progressive disease and ureteral obstruction. Mild to moderate nausea and vomiting occurred in most patients, but none experienced severe ototoxicity or peripheral neuropathy. Over all courses, 73% of the projected dose intensity of CTX and carboplatin and 86% of cisplatin were delivered. Since granulocytopenia and thrombocytopenia were dose-limiting, the addition of colony-stimulating factors that support both myeloid and megakaryocyte precursors may permit further dose intensification.

Original languageEnglish (US)
Pages (from-to)1793-1800
Number of pages8
JournalJournal of Clinical Oncology
Volume9
Issue number10
DOIs
StatePublished - Jan 1 1991

Fingerprint

Carboplatin
Combination Drug Therapy
Cyclophosphamide
Cisplatin
Carcinoma
Second-Look Surgery
Confidence Intervals
Colony-Stimulating Factors
Ureteral Obstruction
Agranulocytosis
Megakaryocytes
Survival
Peripheral Nervous System Diseases
Treatment Failure
Granulocytes
Thrombocytopenia
Ovarian Neoplasms
Laparotomy
Nausea
Vomiting

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cisplatin, carboplatin, and cyclophosphamide combination chemotherapy in advanced-stage ovarian carcinoma : An Eastern Cooperative Oncology Group pilot study. / Grem, Jean L; O'Dwyer, P.; Elson, P.; Simon, N.; Trump, D.; Frontiera, M.; Falkson, G.; Vogl, S.

In: Journal of Clinical Oncology, Vol. 9, No. 10, 01.01.1991, p. 1793-1800.

Research output: Contribution to journalArticle

Grem, Jean L ; O'Dwyer, P. ; Elson, P. ; Simon, N. ; Trump, D. ; Frontiera, M. ; Falkson, G. ; Vogl, S. / Cisplatin, carboplatin, and cyclophosphamide combination chemotherapy in advanced-stage ovarian carcinoma : An Eastern Cooperative Oncology Group pilot study. In: Journal of Clinical Oncology. 1991 ; Vol. 9, No. 10. pp. 1793-1800.
@article{efb97a510b5e4c0e933ea02189d4a8da,
title = "Cisplatin, carboplatin, and cyclophosphamide combination chemotherapy in advanced-stage ovarian carcinoma: An Eastern Cooperative Oncology Group pilot study",
abstract = "Cyclophosphamide (CTX) 600 mg/m2, carboplatin 280 mg/m2, and cisplatin 50 mg/m2 were administered on day 1 every 4 weeks to 41 previously untreated ovarian cancer patients with residual disease greater than 2.0 cm after primary laparotomy. Of 22 patients with measurable disease treated with up to eight cycles of therapy, the overall clinical response rate was 73{\%} (exact 95{\%} confidence interval [CI], 50{\%} to 89{\%}), with 50{\%} complete response (CR). Six of 11 clinical CR (cCR) patients underwent surgical restaging; three pathologic CRs (pCRs) and three pathologic partial responses (pPRs) with residual disease less than 2.0 cm were documented. Fourteen patients had nonmeasurable but assessable disease; the clinical response rate was 57{\%} (CI, 29{\%} to 82{\%}) with two (14{\%}) CRs. Second-look surgery was performed in one of the two cCR patients; a pPR was documented. Five patients with nonassessable disease were stable during chemotherapy; two underwent surgery and had pCRs. The median time to treatment failure (TTF) was 14.8 months, and median survival for the 41 patients is 26.7 months. Overall, 37{\%} of the patients had progression-free intervals of at least 2 years, and 27{\%} have survival times in excess of 3 years. Hematologic toxicity was substantial but manageable, with 58{\%} and 66{\%} experiencing a granulocyte nadir less than 500/μL and a platelet nadir less than 50,000/μL, respectively. One treatment-associated fatality occurred as a result of leukopenic sepsis and renal failure in the setting of progressive disease and ureteral obstruction. Mild to moderate nausea and vomiting occurred in most patients, but none experienced severe ototoxicity or peripheral neuropathy. Over all courses, 73{\%} of the projected dose intensity of CTX and carboplatin and 86{\%} of cisplatin were delivered. Since granulocytopenia and thrombocytopenia were dose-limiting, the addition of colony-stimulating factors that support both myeloid and megakaryocyte precursors may permit further dose intensification.",
author = "Grem, {Jean L} and P. O'Dwyer and P. Elson and N. Simon and D. Trump and M. Frontiera and G. Falkson and S. Vogl",
year = "1991",
month = "1",
day = "1",
doi = "10.1200/JCO.1991.9.10.1793",
language = "English (US)",
volume = "9",
pages = "1793--1800",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "10",

}

TY - JOUR

T1 - Cisplatin, carboplatin, and cyclophosphamide combination chemotherapy in advanced-stage ovarian carcinoma

T2 - An Eastern Cooperative Oncology Group pilot study

AU - Grem, Jean L

AU - O'Dwyer, P.

AU - Elson, P.

AU - Simon, N.

AU - Trump, D.

AU - Frontiera, M.

AU - Falkson, G.

AU - Vogl, S.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - Cyclophosphamide (CTX) 600 mg/m2, carboplatin 280 mg/m2, and cisplatin 50 mg/m2 were administered on day 1 every 4 weeks to 41 previously untreated ovarian cancer patients with residual disease greater than 2.0 cm after primary laparotomy. Of 22 patients with measurable disease treated with up to eight cycles of therapy, the overall clinical response rate was 73% (exact 95% confidence interval [CI], 50% to 89%), with 50% complete response (CR). Six of 11 clinical CR (cCR) patients underwent surgical restaging; three pathologic CRs (pCRs) and three pathologic partial responses (pPRs) with residual disease less than 2.0 cm were documented. Fourteen patients had nonmeasurable but assessable disease; the clinical response rate was 57% (CI, 29% to 82%) with two (14%) CRs. Second-look surgery was performed in one of the two cCR patients; a pPR was documented. Five patients with nonassessable disease were stable during chemotherapy; two underwent surgery and had pCRs. The median time to treatment failure (TTF) was 14.8 months, and median survival for the 41 patients is 26.7 months. Overall, 37% of the patients had progression-free intervals of at least 2 years, and 27% have survival times in excess of 3 years. Hematologic toxicity was substantial but manageable, with 58% and 66% experiencing a granulocyte nadir less than 500/μL and a platelet nadir less than 50,000/μL, respectively. One treatment-associated fatality occurred as a result of leukopenic sepsis and renal failure in the setting of progressive disease and ureteral obstruction. Mild to moderate nausea and vomiting occurred in most patients, but none experienced severe ototoxicity or peripheral neuropathy. Over all courses, 73% of the projected dose intensity of CTX and carboplatin and 86% of cisplatin were delivered. Since granulocytopenia and thrombocytopenia were dose-limiting, the addition of colony-stimulating factors that support both myeloid and megakaryocyte precursors may permit further dose intensification.

AB - Cyclophosphamide (CTX) 600 mg/m2, carboplatin 280 mg/m2, and cisplatin 50 mg/m2 were administered on day 1 every 4 weeks to 41 previously untreated ovarian cancer patients with residual disease greater than 2.0 cm after primary laparotomy. Of 22 patients with measurable disease treated with up to eight cycles of therapy, the overall clinical response rate was 73% (exact 95% confidence interval [CI], 50% to 89%), with 50% complete response (CR). Six of 11 clinical CR (cCR) patients underwent surgical restaging; three pathologic CRs (pCRs) and three pathologic partial responses (pPRs) with residual disease less than 2.0 cm were documented. Fourteen patients had nonmeasurable but assessable disease; the clinical response rate was 57% (CI, 29% to 82%) with two (14%) CRs. Second-look surgery was performed in one of the two cCR patients; a pPR was documented. Five patients with nonassessable disease were stable during chemotherapy; two underwent surgery and had pCRs. The median time to treatment failure (TTF) was 14.8 months, and median survival for the 41 patients is 26.7 months. Overall, 37% of the patients had progression-free intervals of at least 2 years, and 27% have survival times in excess of 3 years. Hematologic toxicity was substantial but manageable, with 58% and 66% experiencing a granulocyte nadir less than 500/μL and a platelet nadir less than 50,000/μL, respectively. One treatment-associated fatality occurred as a result of leukopenic sepsis and renal failure in the setting of progressive disease and ureteral obstruction. Mild to moderate nausea and vomiting occurred in most patients, but none experienced severe ototoxicity or peripheral neuropathy. Over all courses, 73% of the projected dose intensity of CTX and carboplatin and 86% of cisplatin were delivered. Since granulocytopenia and thrombocytopenia were dose-limiting, the addition of colony-stimulating factors that support both myeloid and megakaryocyte precursors may permit further dose intensification.

UR - http://www.scopus.com/inward/record.url?scp=0026096127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026096127&partnerID=8YFLogxK

U2 - 10.1200/JCO.1991.9.10.1793

DO - 10.1200/JCO.1991.9.10.1793

M3 - Article

VL - 9

SP - 1793

EP - 1800

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 10

ER -